-
Archives of Dermatology Dec 1983
Topics: Adult; Dermatitis, Contact; Desonide; Drug Eruptions; Female; Groin; Humans; Intertrigo; Ointments; Patch Tests; Pregnadienetriols
PubMed: 6228195
DOI: No ID Found -
Cutis Jul 2011The objective of this study was to evaluate patients' real-world experiences with desonide hydrogel for the treatment of mild to moderate atopic dermatitis (AD)....
The objective of this study was to evaluate patients' real-world experiences with desonide hydrogel for the treatment of mild to moderate atopic dermatitis (AD). Physicians who participated in this patient-experience program identified eligible participants (age range, < 3 months to 91 years) for treatment with desonide hydrogel 0.05%. The medication was prescribed by each participant's physician according to his/her practice guidelines and was provided to the participant at no charge. Patients (or their parents/guardians) voluntarily participated by providing consent and completing 2 surveys: one at baseline (pretreatment) and the other approximately 3 weeks after initiation of desonide hydrogel treatment (posttreatment). The pretreatment survey included questions about prior topical medication use for AD and satisfaction with prior treatments. The second survey assessed compliance with desonide hydrogel, satisfaction with treatment, characteristics of desonide hydrogel, intent to continue treatment, and willingness to recommend desonide hydrogel to others. A total of 1185 participants completed both the pretreatment and posttreatment surveys. Participant satisfaction with desonide hydrogel was 95% greater than satisfaction with prior topical medications for AD (P < .01). Adherence to treatment with desonide hydrogel was more than 80% based on reports from participants. Eighty-nine percent of participants reported that they would continue to use the medication for their condition if needed and 85% would recommend desonide hydrogel to others. Prescribing physicians received individual summaries of survey responses reported by each of his/her participating patients, which provided valuable feedback regarding participants' perceptions of treatment. Participants reported favorable experiences after treatment with desonide hydrogel compared with prior topical therapies. Desonide is widely prescribed for the treatment of AD.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Data Collection; Dermatitis, Atopic; Desonide; Female; Humans; Hydrogels; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Practice Guidelines as Topic; Practice Patterns, Physicians'; Severity of Illness Index; Young Adult
PubMed: 21916152
DOI: No ID Found -
AAPS PharmSciTech Oct 2014Desonide is a topical corticoid used in the treatment of skin diseases and is marketed in different pharmaceutical dosage forms. Recently, the poor photostability of a...
Desonide is a topical corticoid used in the treatment of skin diseases and is marketed in different pharmaceutical dosage forms. Recently, the poor photostability of a commercially available hair solution after direct exposure to UVA light was verified. In this study, we investigated the ability of the antioxidants ascorbic acid, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), α-tocopherol, and the UV filter benzophenone-3 (BP-3) to prevent the photodegradation of desonide in hair solution (desonide 0.1%) and the stability of the proposed formulation under environmental conditions. The tested antioxidants were not able to prevent the photolysis of desonide, whereas the addition of 0.3% BP-3 enhanced the photostability of the drug. After 15 h of direct exposure to UVA radiation, the desonide remaining content in the hair solution with BP-3 was approximately 98%. Higher photostability was also verified under UVC radiation. Additionally, the results indicated that the formulation was stable under accelerated and room temperature conditions for 70 days, corresponding to the total period of the study.
Topics: Antioxidants; Benzophenones; Chemistry, Pharmaceutical; Dermatologic Agents; Desonide; Excipients; Photochemistry; Spectrophotometry, Ultraviolet; Temperature; Ultraviolet Rays
PubMed: 24871554
DOI: 10.1208/s12249-014-0149-0 -
Drug Development and Industrial Pharmacy Jan 2016Our group previously reported the photoinstability of some desonide topical commercial formulations under direct exposure to UVA radiation.
CONTEXT
Our group previously reported the photoinstability of some desonide topical commercial formulations under direct exposure to UVA radiation.
OBJECTIVE
This study aimed to prepare and characterize a gel-cream containing desonide, with greater photostability than the commercial gel-cream (C-GC). Benzophenone-3 (BP-3) was used as a photostabilizing agent.
METHODS
The gel-cream developed (D-GC) containing BP-3 at 0.1% was prepared and characterized regarding its pH, drug content, spreadability, viscosity, in vitro drug release and in vitro permeation. The in vivo anti-inflammatory effect was assessed by ear edema measurement, croton oil-induced acute skin inflammation and myeloperoxidase assay.
RESULTS AND DISCUSSION
D-GC presented characteristics compatible with topical application, appropriate drug content and good spreadability, and non-Newtonian behavior with pseudoplastic flow. D-GC showed a good photostability profile, presenting a desonide content of 95.70% after 48 h of exposure to UVA radiation, and stability under room conditions during 60 days. The amount of desonide released from D-GC and C-GC was 57.8 and 51.7 µg/cm, respectively, measured using the vertical Franz cell. The in vitro skin permeation showed that desonide reached the site of action of the topical corticosteroids, from both formulations; however, the desonide amount retained in the dermis was lower with D-GC. The in vivo evaluation of topical anti-inflammatory activity indicated that D-GC presented the same biological effect as C-GC.
CONCLUSION
D-GC represents a promising approach to treat dermatological disorders, since it presented satisfactory physicochemical characteristics, the same biological activity as C-GC and superior photostability, conferred by the addition of BP-3 at 0.1%.
Topics: Animals; Anti-Inflammatory Agents; Benzophenones; Chemistry, Pharmaceutical; Croton Oil; Dermatitis, Contact; Dermatologic Agents; Desonide; Disease Models, Animal; Ear; Gels; Glucocorticoids; Humans; Male; Mice; Skin; Skin Cream; Ultraviolet Rays
PubMed: 25775013
DOI: 10.3109/03639045.2015.1022554 -
AAPS PharmSciTech May 2021This research aimed to develop a novel drug delivery system to improve treatment of skin disorders. The system is comprised of a Carbopol 980-based nanoemulgel (NE-gel)...
This research aimed to develop a novel drug delivery system to improve treatment of skin disorders. The system is comprised of a Carbopol 980-based nanoemulgel (NE-gel) containing a desonide (DES; 0.05%, w/w) nanoemulsion (NE), which has a small particle size, high encapsulation efficiency, good thermodynamic stability, good permeation ability, and high skin retention. DES-loaded NE (DES-NE) was prepared by high-pressure homogenization. The developed formulation was characterized by differential scanning calorimetry (DSC), X-ray diffraction, drug release, skin permeation, and drug retention. DES in vitro release and skin permeation studies with different formulations of artificial membrane and rat abdominal skin were performed with the Franz diffusion cell system. Confocal laser scanning microscopy (CLSM) was used to detect the localization and permeation pathways of drugs in the skin. Compared with commercially available gel (CA-gel) and NE, the NE-gel release process conformed to the Higuchi release model (R = 0.9813). NE-gel prolonged the drug release time and allowed for reduced administration dose and frequency. The unit cumulative permeation of NE and NE-gel through the skin for 12 h was 63.13 ± 2.78 and 42.53 ± 2.06 μg/cm, respectively, values significantly higher (p < 0.01) than that of the CA-gel (30.65 ± 1.25 μg/cm) and CA-cream (15.21 ± 0.97 μg/cm). The DES-NE and DES NE-gel skin drug retention was significantly higher than commercially available formulations (p < 0.01). Hence, the prepared NE-gel is a potential vehicle for improved topical DES delivery for better treatment of skin disorders.
Topics: Administration, Topical; Animals; Colloids; Desonide; Drug Delivery Systems; Emulsions; Excipients; Microscopy, Confocal; Nanogels; Particle Size; Rats; Skin; Skin Absorption
PubMed: 34031790
DOI: 10.1208/s12249-021-02035-5 -
Pharmaceutical Development and... Jul 2022Nanotechnological products have been used as strategies to optimize the therapy and minimize the side effects of topical corticoids. The objective of this study was to...
Nanotechnological products have been used as strategies to optimize the therapy and minimize the side effects of topical corticoids. The objective of this study was to develop hydrogels by the addition of sclerotium gum to the suspensions of desonide-loaded açai oil-based nanocapsules and to study their biological effect using an animal model of acute skin inflammation. The hydrogels presented a pH compatible with topical application (4.4 to 5.0), nanometric mean diameter (131 to 165 nm), pseudoplastic behavior, and stability under room conditions during 30 days. The skin permeation/penetration study demonstrated that a higher amount of desonide ( < 0.05) was retained in the epidermis from the nanotechnological-hydrogels (0.33 to 0.36 µg.cm) in comparison to the commercial gel cream (0.16 µg.cm). In the dermis, the nanostructured hydrogels promoted a lower DES retention compared to the non-nanostructured formulations ( < 0.05). This result may indicate a smaller amount of drug reaching the bloodstream and, thus, fewer side effects can be expected. Concerning the anti-inflammatory effect, the developed hydrogels reduced both ear edema and inflammatory cell infiltration, showing an effect comparable to the commercially available formulation, which presents twice the drug concentration. The hydrogels developed may be considered a promising approach to treat dermatological disorders.
Topics: Animals; Anti-Inflammatory Agents; Desonide; Glucocorticoids; Hydrogels; Nanocapsules
PubMed: 35850635
DOI: 10.1080/10837450.2022.2103147 -
Proceedings of the National Academy of... Mar 2022Identifying inhibitors of pathogenic proteins is the major strategy of targeted drug discoveries. This strategy meets challenges in targeting neurodegenerative disorders...
Identifying inhibitors of pathogenic proteins is the major strategy of targeted drug discoveries. This strategy meets challenges in targeting neurodegenerative disorders such as Huntington’s disease (HD), which is mainly caused by the mutant huntingtin protein (mHTT), an “undruggable” pathogenic protein with unknown functions. We hypothesized that some of the chemical binders of mHTT may change its conformation and/or stability to suppress its downstream toxicity, functioning similarly to an “inhibitor” under a broader definition. We identified 21 potential mHTT selective binders through a small-molecule microarray–based screening. We further tested these compounds using secondary phenotypic screens for their effects on mHTT-induced toxicity and revealed four potential mHTT-binding compounds that may rescue HD-relevant phenotypes. Among them, a Food and Drug Administration–approved drug, desonide, was capable of suppressing mHTT toxicity in HD cellular and animal models by destabilizing mHTT through enhancing its polyubiquitination at the K6 site. Our study reveals the therapeutic potential of desonide for HD treatment and provides the proof of principle for a drug discovery pipeline: target-binder screens followed by phenotypic validation and mechanistic studies.
Topics: Animals; Desonide; Disease Models, Animal; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Mutation; Protein Stability
PubMed: 35238684
DOI: 10.1073/pnas.2114303119 -
Cutis Jul 2011
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Dermatitis, Atopic; Desonide; Humans; Hydrogels; Medication Adherence; United States
PubMed: 21916150
DOI: No ID Found -
Southern Medical Journal Mar 1973
Clinical Trial Comparative Study
Topics: Acetals; Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Dermatitis; Fluocinolone Acetonide; Flurandrenolone; Forearm; Humans; Hydrocortisone; Lichen Planus; Prednisolone; Psoriasis; Triamcinolone Acetonide; Vasoconstrictor Agents
PubMed: 4570656
DOI: 10.1097/00007611-197303000-00011 -
JAMA Dec 1973
Clinical Trial Comparative Study
Topics: Acetals; Administration, Topical; Anti-Inflammatory Agents; Clinical Trials as Topic; Drug Evaluation; Fluocinolone Acetonide; Humans; Ketosteroids; Pregnanetriol; Skin Diseases
PubMed: 4587318
DOI: 10.1001/jama.226.13.1569d